Compare AEYE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | ONCY |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 80.5M |
| IPO Year | 2011 | 2002 |
| Metric | AEYE | ONCY |
|---|---|---|
| Price | $6.66 | $0.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $17.33 | $4.16 |
| AVG Volume (30 Days) | 63.8K | ★ 1.3M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,311,000.00 | N/A |
| Revenue This Year | $8.25 | N/A |
| Revenue Next Year | $10.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $5.31 | $0.44 |
| 52 Week High | $16.39 | $1.32 |
| Indicator | AEYE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 29.93 |
| Support Level | $6.61 | N/A |
| Resistance Level | $7.32 | $0.89 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 9.76 | 24.48 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.